Seite 1 von 64
Neuester Beitrag: 08.05.21 08:31
|Eröffnet am:||26.10.17 19:55||von: BICYPAPA||Anzahl Beiträge:||2.595|
|Neuester Beitrag:||08.05.21 08:31||von: BigBen2013||Leser gesamt:||365.413|
|Seite: < 1 | 2 | 3 | 4 | 62 | 63 | 64 64 >|
im Mai und Juni stehen einige Termine an, die sollten uns über die 7€ verhelfen...LG
#587 Mogli: HDP nimmt nächste Woche in Shanghai am „ChinaBio Forum 2021“teil.
PEGS The Essential Protein Engineering Summit 11. - 13. Mai 2021
AACR Annual Meeting 17. - 21. Mai 2021
Ordentliche Hauptversammlung 18. Mai 2021 11:00
MGTA-145 Upcoming Scientific Conference Presentations:
Magenta will present preliminary MGTA-145 Phase 2 data in Multiple Myeloma patients at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually June 4-8, 2021, and at the European Hematology Association (EHA) Congress, to be held virtually June 9-17, 2021.
MGTA-145 Stem Cell Mobilization and Collection Recent and Planned Activity:
Phase 2 clinical trial in Multiple Myeloma is ongoing at Stanford University, evaluating the ability of MGTA-145, in combination with plerixafor, to mobilize stem cells for collection prior to autologous stem cell transplant. This 25-patient, investigator-initiated trial will also measure engraftment and disease outcome measures, with stem cell mobilization as the primary endpoint. Preliminary results will be presented at ASCO and EHA and final clinical data from this trial are expected in the second half of 2021.
Phase 2 clinical trial in collaboration with the National Marrow Donor Program®/Be The Match®, evaluating MGTA-145, in combination with plerixafor, in the mobilization and collection of stem cells from allogeneic donors for transplant in patients with Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) and Myelodysplastic Syndromes (MDS). Initial data from this trial are expected in the second half of 2021.
Initiate Phase 2 clinical trial in Sickle Cell Disease in collaboration with bluebird bio in the second half of 2021 to evaluate the utility of MGTA-145, in combination with plerixafor, for the mobilization and collection of stem cells in patients with Sickle Cell Disease where mobilization and collection is difficult and there is a clear unmet medical need.
MGTA-117 and CD45-ADC Targeted Conditioning Programs Recent and Planned Activity:
MGTA-117 Investigational New Drug (IND) filing anticipated mid-2021. If the IND is accepted by the FDA, Magenta plans to initiate a Phase 1/2 clinical trial evaluating MGTA-117 in patients with AML and MDS. Magenta expects to assess initial safety and pharmacokinetic data internally in the fourth quarter of 2021, and also expects to be able to provide an update regarding the study’s progress within the dose escalation study design.
Magenta recently completed its GLP toxicology studies, its GMP manufacturing process and has finished its pre-IND